Annelise Bennaceur holds a Doctor of Medicineand Doctor of Sciences degrees. She is Professor of Hematology at the Facultyof Medicine - Paris Saclay University. She is a pionner in France in thedevelopment of pluripotent stem cell research and she was the first togenerate embryonic stem cell lines in France. Her expertise includes basicand clinical research h in the anti-tumor immunotherapy derived from iPSCs. Shecurrently serves as Chairman of the Onco-hematology Laboratory in Paris SaclayUniveristy Hospitals. In 2018 she founded the Center of IPSC Therapies(CiTHERA), a cGMP-grade iPS Cell Therapy Manufacturing facility linked toInserm Research Unit U1310. She coordinates 'INGESTEM,' a NationalInfrastructure program under the "Investissement d'Avenir"initiative, dedicated to industrial pluripotent stem cell development forinnovative cancer therapies.
Annelise Bennaceur participated in revising thebioethics law in France and served as an expert member of the commission forclinical trials in cell therapy at the French Regulatory MedicinesAgency. She is on the board director of the international ‘GlobalAlliance of iPSC Therapies’ GAiT, dedicated to the clinical use of iPSCs and ofthe European Network Cost-Action ‘Haplo-iPSC’.
As an international expert in pluripotent stemcells and immuno-oncology, she brings her major expertise to IPSIRIUS, in thefield of cancer stem cells and iPSC-derived engineering technologies. Prof.Bennaceur is the Officer of the Legion of Honour, and of the Order of Merit ofthe Academic Palms.
